MX2019004847A - Compuesto de amino pirazolopirimidina usado como inhibidor del receptor de tirosina cinasa del factor neurotrófico. - Google Patents

Compuesto de amino pirazolopirimidina usado como inhibidor del receptor de tirosina cinasa del factor neurotrófico.

Info

Publication number
MX2019004847A
MX2019004847A MX2019004847A MX2019004847A MX2019004847A MX 2019004847 A MX2019004847 A MX 2019004847A MX 2019004847 A MX2019004847 A MX 2019004847A MX 2019004847 A MX2019004847 A MX 2019004847A MX 2019004847 A MX2019004847 A MX 2019004847A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
kinase receptor
neurotrophic factor
receptor inhibitor
compound used
Prior art date
Application number
MX2019004847A
Other languages
English (en)
Inventor
Wu Wei
Yang Ling
Xu Hongjiang
Wang Shanchun
Han Yongxin
Zhu Li
Hu Yuandong
Dai Liguang
Duan Xiaowei
Yang Yanqing
Sun Yinghui
Peng Yong
Kong Fansheng
Luo Hong
Guo Meng
Zhong Zhaobai
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2019004847A publication Critical patent/MX2019004847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto de amino pirazolopirimidina tal como se representa mediante la siguiente fórmula estructural usado como un inhibidor del receptor de tirosina cinasa del factor neurotrófico. El compuesto puede inhibir la actividad de la Trk cinasa y puede tratar enfermedades mediadas por un receptor de tirosina cinasa Trk en mamíferos.
MX2019004847A 2016-10-28 2017-10-27 Compuesto de amino pirazolopirimidina usado como inhibidor del receptor de tirosina cinasa del factor neurotrófico. MX2019004847A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610970314 2016-10-28
CN201710044000 2017-01-21
PCT/CN2017/108100 WO2018077246A1 (zh) 2016-10-28 2017-10-27 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物

Publications (1)

Publication Number Publication Date
MX2019004847A true MX2019004847A (es) 2019-08-29

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004847A MX2019004847A (es) 2016-10-28 2017-10-27 Compuesto de amino pirazolopirimidina usado como inhibidor del receptor de tirosina cinasa del factor neurotrófico.

Country Status (16)

Country Link
US (1) US10829492B2 (es)
EP (1) EP3533796B1 (es)
JP (1) JP7046940B2 (es)
KR (1) KR102616249B1 (es)
CN (1) CN109890820B (es)
AU (1) AU2017348826B2 (es)
BR (1) BR112019008656A8 (es)
CA (1) CA3041942C (es)
DK (1) DK3533796T3 (es)
ES (1) ES2896943T3 (es)
HU (1) HUE057733T2 (es)
MX (1) MX2019004847A (es)
PL (1) PL3533796T3 (es)
PT (1) PT3533796T (es)
RU (1) RU2764523C2 (es)
WO (1) WO2018077246A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3674307T3 (pl) 2017-08-23 2023-11-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Związek makrocykliczny zawierający ugrupowanie aminopirazolu i pirymidyny oraz kompozycja farmaceutyczna i i ch zastosowanie
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
CN113166156B (zh) * 2018-12-07 2024-02-27 贝达药业股份有限公司 酪氨酸激酶抑制剂、组成及其方法
US20220177477A1 (en) 2019-03-19 2022-06-09 Central China Normal University Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
CN115551863A (zh) * 2020-06-11 2022-12-30 贝达药业股份有限公司 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075A (zh) * 2020-11-03 2022-05-06 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
WO2022235054A1 (ko) * 2021-05-03 2022-11-10 주식회사 제이비케이랩 2,6-디클로로-4-(4-(4-하이드록시사이클로헥실아미노)-7h-피롤로[2,3-d]피리미딘-5-일)페놀을 유효성분으로 포함하는 암의 예방, 개선 또는 치료용 약학적 조성물
WO2023006057A1 (zh) * 2021-07-30 2023-02-02 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
WO2023011616A1 (zh) * 2021-08-06 2023-02-09 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
MX2010012457A (es) 2008-05-13 2010-12-07 Irm Llc Heterociclos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa.
AU2009266956B2 (en) 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors
PL2350075T3 (pl) 2008-09-22 2014-07-31 Array Biopharma Inc Podstawione związki imidazo[1,2b]pirydazynowe jako inhibitory kinaz Trk
BRPI0919873B8 (pt) 2008-10-22 2021-05-25 Array Biopharma Inc compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
BR112014014276A2 (pt) 2011-12-12 2017-06-13 Dr Reddys Laboratories Ltd composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor
SG11201506514QA (en) 2013-02-19 2015-09-29 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
WO2014143242A1 (en) * 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104650092B (zh) * 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
PT3077397T (pt) * 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
EP4420732A2 (en) 2014-12-15 2024-08-28 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors

Also Published As

Publication number Publication date
CA3041942C (en) 2023-03-14
RU2019114600A (ru) 2020-11-30
CN109890820A (zh) 2019-06-14
US10829492B2 (en) 2020-11-10
PT3533796T (pt) 2021-11-18
EP3533796A4 (en) 2020-06-03
US20190352306A1 (en) 2019-11-21
DK3533796T3 (da) 2021-11-08
CN109890820B (zh) 2020-11-03
JP2019537588A (ja) 2019-12-26
BR112019008656A8 (pt) 2022-06-07
AU2017348826A1 (en) 2019-05-23
EP3533796A1 (en) 2019-09-04
KR20190067913A (ko) 2019-06-17
RU2019114600A3 (es) 2021-02-20
AU2017348826B2 (en) 2021-12-02
BR112019008656A2 (pt) 2019-07-09
EP3533796B1 (en) 2021-09-29
RU2764523C2 (ru) 2022-01-18
HUE057733T2 (hu) 2022-06-28
WO2018077246A1 (zh) 2018-05-03
PL3533796T3 (pl) 2022-01-17
CA3041942A1 (en) 2018-05-03
JP7046940B2 (ja) 2022-04-04
KR102616249B1 (ko) 2023-12-21
ES2896943T3 (es) 2022-02-28

Similar Documents

Publication Publication Date Title
MX2019004847A (es) Compuesto de amino pirazolopirimidina usado como inhibidor del receptor de tirosina cinasa del factor neurotrófico.
PH12016502252A1 (en) Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
MX2022000711A (es) Inhibidores de parp1.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MX2018004892A (es) Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr.
EA201991198A1 (ru) АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
PH12017500854A1 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
EA201991197A1 (ru) БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
TW201613916A (en) TANK-binding kinase inhibitor compounds
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
MX2023004221A (es) Inhibidores de rad51.
MX2020001979A (es) Macrociclo que contiene aminopirazol y pirimidina y composicion farmaceutica y uso de la misma.
PH12019550235A1 (en) Kinase inhibitors and uses thereof
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
CA3082254A1 (en) Heterocyclic compounds as kinase inhibitors
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
WO2015114638A3 (en) Use of casein kinase i inhibitors for depleting stem cells
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.